Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Relmada Therapeutics Q2 EPS $(1.56) Misses $(1.47) Estimate

Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(1.56) per share which missed the analyst consensus estimate of $(1.47) by 6.12 percent. This is a 113.7 percent decrease over losses of $(0.73) per share

byBill Haddad

August 10, 2021

1 minute read

Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(1.56) per share which missed the analyst consensus estimate of $(1.47) by 6.12 percent. This is a 113.7 percent decrease over losses of $(0.73) per share from the same period last year.